Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Recommendation of “Buy” by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned an average rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $65.50.

Several analysts have issued reports on the company. Raymond James Financial reissued a “strong-buy” rating on shares of Mirum Pharmaceuticals in a report on Tuesday, May 13th. JMP Securities boosted their price objective on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the company a “market outperform” rating in a research report on Friday, May 9th. HC Wainwright restated a “buy” rating and issued a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Finally, Wall Street Zen downgraded Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 564 shares of the company’s stock in a transaction on Wednesday, July 2nd. The stock was sold at an average price of $48.25, for a total transaction of $27,213.00. Following the completion of the sale, the senior vice president owned 2,903 shares in the company, valued at $140,069.75. This represents a 16.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 22.87% of the stock is currently owned by corporate insiders.

Institutional Trading of Mirum Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. CWM LLC lifted its holdings in shares of Mirum Pharmaceuticals by 259.4% during the 1st quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after acquiring an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $35,000. Comerica Bank lifted its stake in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in Mirum Pharmaceuticals in the 4th quarter worth approximately $42,000.

Mirum Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ MIRM opened at $50.47 on Thursday. The firm’s 50 day moving average price is $46.64 and its 200-day moving average price is $45.62. The company has a market cap of $2.50 billion, a PE ratio of -31.35 and a beta of 0.97. Mirum Pharmaceuticals has a 52-week low of $34.47 and a 52-week high of $54.23. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. The company had revenue of $111.59 million during the quarter, compared to analyst estimates of $98.47 million. During the same quarter in the previous year, the company posted ($0.54) earnings per share. Mirum Pharmaceuticals’s revenue was up 61.2% compared to the same quarter last year. On average, equities research analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.